<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Example of epinephrine infusion (4 micrograms/mL) - Adult</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Example of epinephrine infusion (4 micrograms/mL) - Adult</h1>
<div class="graphic"><div class="figure"><div class="ttl">Example of epinephrine infusion (4 micrograms/mL) - Adult</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="3">Example of preparation of epinephrine infusion for refractory symptoms of anaphylaxis (adult patient) for emergency/critical care units</td> </tr> <tr> <td class="subtitle2" colspan="3">Final concentration: Epinephrine 4 micrograms/mL</td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Preparation</td> </tr> <tr> <td colspan="3"> <ol> <li><strong>CHECK</strong> vial strength.</li> </ol> </td> </tr> <tr> <td colspan="3"> <ol start="2"> <li>Add 1 milligram of epinephrine to 250 mL bag of 0.9% normal saline (NS) or 5% dextrose water (D5W) <ul> <li>If you have 0.1 mg/mL strength epinephrine (may also be labeled 1:10,000) use 10 mL to deliver 1 mg to bag*</li> <li>If you have 1 mg/mL strength epinephrine (may also be labeled 1:1000) use 1 mL to deliver 1 mg to bag*</li> </ul> </li> </ol> </td> </tr> <tr> <td class="subtitle3_left_align" colspan="3">Administration</td> </tr> <tr> <td class="indent1" colspan="3"> <ul> <li>Start the epinephrine infusion at <strong>0.1 microgram/kg/minute</strong> using a programmable infusion pump while continuously monitoring the patient's cardiac rhythm and blood pressure (ie, approximately 6 to 10 micrograms/minute in most adults).</li> <li>Using a body weight of 80 kg as an example, you can determine the infusion rate to deliver a dose of 0.1 microgram/kg/minute from a 4 micrograms/mL bag as follows: <ol class="numbers_no_heading"> <li>Multiply 0.1 microgram/kg/minute dose by 80 kg body weight to determine dose in micrograms/minute (= 8 micrograms/minute).</li> <li>Use this table to convert 8 micrograms/minute to infusion rate of 2 mL/minute (= 120 mL/hour).</li> </ol> </li> <li>Every 2 to 3 minutes, increase the infusion rate by approximately one-half of the starting rate until the blood pressure and perfusion improve. For more detail, refer to the UpToDate topic on emergency treatment of anaphylaxis.</li> <li>In morbidly obese adults, we suggest initiating the infusion using a standard, ie, non-weight-based dose (eg, up to 10 micrograms/minute initially) and titrating to effect.</li> </ul> </td> </tr> <tr> <td class="subtitle2">Adult infusion dose</td> <td class="subtitle2" colspan="2">Administration rate for infusion pump to deliver adult dose shown</td> </tr> <tr> <td class="subtitle3">micrograms per minute</td> <td class="subtitle3">mL per minute</td> <td class="subtitle3">mL per hour</td> </tr> <tr> <td class="centered">1</td> <td class="centered">0.25</td> <td class="centered">15</td> </tr> <tr class="highlight_blue_text"> <td class="centered">2</td> <td class="centered">0.5</td> <td class="centered">30</td> </tr> <tr> <td class="centered">3</td> <td class="centered">0.75</td> <td class="centered">45</td> </tr> <tr class="highlight_blue_text"> <td class="centered">4</td> <td class="centered">1</td> <td class="centered">60</td> </tr> <tr> <td class="centered">5</td> <td class="centered">1.25</td> <td class="centered">75</td> </tr> <tr class="highlight_blue_text"> <td class="centered">6</td> <td class="centered">1.5</td> <td class="centered">90</td> </tr> <tr> <td class="centered">7</td> <td class="centered">1.75</td> <td class="centered">105</td> </tr> <tr class="highlight_blue_text"> <td class="centered">8</td> <td class="centered">2</td> <td class="centered">120</td> </tr> <tr> <td class="centered">9</td> <td class="centered">2.25</td> <td class="centered">135</td> </tr> <tr class="highlight_blue_text"> <td class="centered">10</td> <td class="centered">2.5</td> <td class="centered">150</td> </tr> <tr> <td class="centered">11</td> <td class="centered">2.75</td> <td class="centered">165</td> </tr> <tr class="highlight_blue_text"> <td class="centered">12</td> <td class="centered">3</td> <td class="centered">180</td> </tr> <tr> <td class="centered">13</td> <td class="centered">3.25</td> <td class="centered">195</td> </tr> <tr class="highlight_blue_text"> <td class="centered">14</td> <td class="centered">3.5</td> <td class="centered">210</td> </tr> <tr> <td class="centered">15</td> <td class="centered">3.75</td> <td class="centered">225</td> </tr> <tr class="highlight_blue_text"> <td class="centered">16</td> <td class="centered">4</td> <td class="centered">240</td> </tr> <tr> <td colspan="3"> <ul> <li>The above table is provided as an example. There are other acceptable concentrations.</li> <li>Intravenous epinephrine, like all vasopressors, can cause life-threatening hypertension, cardiac ischemia, and ventricular arrhythmias. It should be administered <strong>only</strong> by clinicians trained and experienced in dose titration of intravenous epinephrine using continuous noninvasive electronic monitoring of heart rate and blood pressure.</li> <li>Epinephrine is an ischemia-causing agent and vesicant. Monitor infusion site for extravasation. Central venous catheter administration is preferred when available. Refer to the Lexicomp drug reference for information on managing extravasation including infiltration of phentolamine.</li> <li>To reduce the risk of making a medication error, we suggest that centers have available an institutionally approved protocol for epinephrine infusion that includes steps on how to prepare and administer the infusion by programmable infusion pump and standard concentration(s).</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong>Albuterol –</strong> For bronchospasm resistant to IM epinephrine, give albuterol 2.5 mg inhaled via nebulizer. Dilute in saline if using a concentrated albuterol solution (≥0.5%). Repeat, as needed.</td> </tr> <tr> <td class="indent1" colspan="3"><strong>H1 antihistamine –</strong> Consider giving diphenhydramine 1 mg/kg (maximum 50 mg IV, over 5 minutes) or cetirizine (children aged 6 months to 5 years can receive 2.5 mg IV, those 6 to 11 years of age can receive 5 or 10 mg IV, over 2 minutes).</td> </tr> <tr> <td class="indent1" colspan="3"><strong>H2 antihistamine –</strong> Consider giving famotidine 0.25 mg/kg (maximum 20 mg) IV, over at least 2 minutes.</td> </tr> <tr> <td class="indent1" colspan="3"><strong>Glucocorticoid –</strong> Consider giving methylprednisolone 1 mg/kg (maximum 125 mg) IV.</td> </tr> <tr> <td class="indent1" colspan="3"><strong>Monitoring –</strong> Continuous noninvasive hemodynamic monitoring and pulse oximetry monitoring should be performed. Urine output should be monitored in patients receiving IV fluid resuscitation for severe hypotension or shock.</td> </tr> <tr> <td class="subtitle1_single" colspan="3">Treatment of refractory symptoms:</td> </tr> <tr> <td class="indent1" colspan="3"><strong>Epinephrine infusion<sup>¶</sup></strong> <strong>–</strong> In patients with inadequate response to IM epinephrine and IV saline, give epinephrine continuous infusion at 0.1 to 1 microgram/kg/minute, titrated to effect.</td> </tr> <tr> <td class="indent1" colspan="3"><strong>Vasopressors</strong><sup>¶</sup> <strong>–</strong> Patients may require large amounts of IV crystalloid to maintain blood pressure. Some patients may require a second vasopressor (in addition to epinephrine). All vasopressors should be given by infusion pump, with the doses titrated continuously according to blood pressure and cardiac rate/function monitored continuously and oxygenation monitored by pulse oximetry.</td> </tr> <tr> <td class="indent1" colspan="3"><strong>Glucagon –</strong> Patients on beta blockers may not respond to epinephrine and can be given glucagon 20 to 30 micrograms/kg (maximum 1 mg) IV over 5 minutes. Rapid administration of glucagon can cause vomiting.</td> </tr> </tbody></table></div><div class="graphic_footnotes">* Unused diluted solutions should be discarded within 24 hours or less of preparation, depending on local standards.</div><div class="graphic_reference">References:
<ol>
<li>Gahart BL, Nazareno AR, Ortega MQ. Gahart's 2016 Intravenous Medications: A Handbook for Nurses and Health Professionals, 32nd ed, Elsevier-Mosby, St. Louis, MO.</li>
<li>Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.</li>
</ol></div><div id="graphicVersion">Graphic 75682 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
